Patent intelligence · US
US 11351124
Sustained release of formulations of local anesthetics
Sustained release of formulations of local anesthetics
Patent details — US 11351124
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 7, 2022
- Expiration
- Jun 2, 2042
- Applicant
- Eupraxia Pharmaceuticals Inc.
- Claims
- 17
- CPC classes
- A61K, A61K31/445, A61K9/0024, A61K9/0085
Quick answer
US 11351124 (Sustained release of formulations of local anesthetics) is held by Eupraxia Pharmaceuticals Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Eupraxia Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/445, A61K9/0024, A61K9/0085, A61K9/5026, A61K9/5089
More from Eupraxia Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11219604
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
granted -
US 9987233
Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith
granted
Frequently asked questions
What is US patent 11351124?
US 11351124 (Sustained release of formulations of local anesthetics) is held by Eupraxia Pharmaceuticals Inc.. Status: granted. Granted Jun 7, 2022. Expires Jun 2, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11351124?
Eupraxia Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11351124 expire?
Our index shows an expiration date of Jun 2, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.